KPT 9274

Drug Profile

KPT 9274

Alternative Names: KPT-9274

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors; P21 activated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 08 Sep 2017 Preliminary efficacy and adverse events data from a phase I trial in Solid tumours and Non-Hodgkin's lymphoma presented at the 42nd European Society of Medical Oncology Congress (ESMO-2017)
  • 01 Apr 2017 Preclinical data in Non-Hodgkin's lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Mar 2017 Karyopharm Therapeutics has patents pending for KPT 9274 in USA, countries outside USA and patent cooperation treaty (PCT)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top